Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. Type 508 Accommodation and the title of the report in the subject line of e-mail.
Public Health Dispatch: Acute Flaccid Paralysis Associated with
Circulating Vaccine-Derived Poliovirus --- Philippines, 2001
Three cases of acute flaccid paralysis (AFP) associated with circulating
vaccine-derived poliovirus (cVDPV) isolates were reported in the Philippines during March
15--July 26, 2001. The first case-patient, a child aged 8 years from northern Mindanao island
(500 miles south of Manila) who had received 3 doses of oral polio vaccine (OPV), had onset
of paralysis on March 15. A second child, aged 3 years from Laguna province on
Luzon island (60 miles south of Manila) who had received 3 OPV doses, presented with signs
of meningitis but no paralysis on July 23. A third child, aged 14 months from Cavite
province (25 miles from Manila and 45 miles north of Laguna province) who had received
2 OPV doses, had onset of paralysis on July 26. No patients had traveled outside of
their province of residence since birth. Characterization of isolates from the three
patients revealed type 1 polioviruses derived from Sabin vaccine strain type 1, with a 3%
genetic sequence difference between Sabin 1 vaccine and vaccine-derived poliovirus
(VDPV) isolates. The three polioviruses are not identical but are closely related (>99%
sequence homology); they also appear to share an identical recombination site with a
nonpolio enterovirus in the noncapsid region of the genome.
Following cVDPV outbreaks in the Dominican Republic and Haiti (Hispaniola)
during 2000--2001 (1), the global polio laboratory network implemented additional testing
requirements for all polioviruses under investigation, prospectively and
retrospectively. Both an antigenic-based (ELISA) and a molecular-based test (probe hybridization)
are used to determine whether a poliovirus is wild or derived from vaccine (i.e.,
intratypic differentiation [ITD]). Divergent ITD results (one test showing vaccine-derived and
the other wild-type virus) for any poliovirus isolate now require genomic sequencing of
the suspect isolates. Retrospective testing of >2,000 vaccine-related isolates from AFP
cases globally has revealed no additional cVDPVs, although testing results of other isolates
in the laboratory network are pending. The cVDPVs from the Philippines were
detected after the implementation of new testing requirements for prospective virus
investigations.
In response to these cases, the Department of Health in the Philippines 1)
enhanced surveillance by active record review for AFP cases in hospitals and other
health-care facilities in the affected and neighboring provinces, 2) established surveillance to
conduct virologic investigations of aseptic meningitis at major health-care facilities, 3)
collected stool samples from healthy contacts of case-patients, 4) conducted field
investigations of clustered AFP cases to determine the extent of cVDPV circulation, and 5)
assessed polio vaccination coverage in these communities. The investigations have
found no unreported cases, although some AFP cases remain under investigation. To
interrupt cVDPV circulation, a large-scale mass vaccination campaign with OPV is planned.
Low routine vaccination coverage is one of the most important causes of
VDPV. Because the location of the originating events is unknown, the contribution of
other factors is difficult to assess; however, a combination of two concurrent events within
the virus is necessary for cVDPV emergence: reversion of attenuating mutations to
increase neurovirulence, and a presumed increase in transmission characteristics that might
be related to recombination with a nonpolio enterovirus. The molecular basis for the
second property is not understood.
Wild poliovirus was last reported in the Philippines in 1993
(2), and national vaccination rounds were last conducted in the Philippines in 1997 followed by subnational
immunization days in 1998 and 1999. Among the areas covered were Cebu, Davao,
Manila, and parts of Mindanao; however, coverage did not extend to the three provinces
now
reporting cVDPV cases. Routine coverage with 3 OPV doses has been
approximately 80% nationwide since the early 1990s; however, coverage gaps are likely, particularly
in slum areas.
Travelers to the Philippines should ensure that they are vaccinated
appropriately against polio according to national recommendations
(3).
Reported by: National Epidemiology Center, National Center for Disease Prevention
and Control, Research Institute of Tropical Medicine, Dept of Health; World Health
Organization, Manila, Philippines. Regional Reference Laboratory, Victorian Infectious Diseases
Reference Laboratory, Fairfield, Victoria, Australia. Global Specialized Laboratory, National Institute
of Infectious Diseases, Tokyo, Japan. Vaccines and Biologicals Dept, World
Health Organization, Geneva, Switzerland. Respiratory and Enteric Viruses Br, Div of Viral
and Rickettsial Diseases, National Center for Infectious Diseases; Vaccine Preventable
Disease Eradication Div, National Immunization Program, CDC.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of
Health and Human Services.
References to non-CDC sites on the Internet are
provided as a service to MMWR readers and do not constitute or imply
endorsement of these organizations or their programs by CDC or the U.S.
Department of Health and Human Services. CDC is not responsible for the content
of pages found at these sites.
Disclaimer
All MMWR HTML versions of articles are electronic conversions from ASCII text
into HTML. This conversion may have resulted in character translation or format errors in the HTML version.
Users should not rely on this HTML document, but are referred to the electronic PDF version and/or
the original MMWR paper copy for the official text, figures, and tables.
An original paper copy of this issue can be obtained from the Superintendent of Documents,
U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800.
Contact GPO for current prices.
**Questions or messages regarding errors in formatting should be addressed to
mmwrq@cdc.gov.
